297 related articles for article (PubMed ID: 31618704)
21. Induction chemotherapy with docetaxel, cisplatin and capecitabine, followed by combined cetuximab and radiotherapy in patients with locally advanced inoperable squamous cell carcinoma of the head and neck: a phase I-II study.
Perri F; Muto P; Argenone A; Ionna F; Longo F; Fulciniti F; Sandomenico F; Daponte A; Caponigro F
Oncology; 2013; 84(4):251-4. PubMed ID: 23428719
[TBL] [Abstract][Full Text] [Related]
22. Patritumab with Cetuximab plus Platinum-Containing Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: An Open-Label, Phase Ib Study.
Dillon MT; Grove L; Newbold KL; Shaw H; Brown NF; Mendell J; Chen S; Beckman RA; Jennings A; Ricamara M; Greenberg J; Forster M; Harrington KJ
Clin Cancer Res; 2019 Jan; 25(2):487-495. PubMed ID: 30327312
[TBL] [Abstract][Full Text] [Related]
23. Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial.
Caponigro F; Di Gennaro E; Ionna F; Longo F; Aversa C; Pavone E; Maglione MG; Di Marzo M; Muto P; Cavalcanti E; Petrillo A; Sandomenico F; Maiolino P; D'Aniello R; Botti G; De Cecio R; Losito NS; Scala S; Trotta A; Zotti AI; Bruzzese F; Daponte A; Calogero E; Montano M; Pontone M; De Feo G; Perri F; Budillon A
BMC Cancer; 2016 Nov; 16(1):918. PubMed ID: 27884140
[TBL] [Abstract][Full Text] [Related]
24. Biweekly cetuximab in combination with platinum and 5-fluorouracil in metastatic head and neck carcinoma.
Surmeli ZG; Ozveren A; Arslan C; Degirmenci M; Karaca B; Uslu R
Indian J Cancer; 2019; 56(1):4-8. PubMed ID: 30950435
[TBL] [Abstract][Full Text] [Related]
25. Randomized phase 3 noninferiority trial of radiotherapy and cisplatin vs radiotherapy and cetuximab after docetaxel-cisplatin-fluorouracil induction chemotherapy in patients with locally advanced unresectable head and neck cancer.
Hitt R; Mesía R; Lozano A; Iglesias Docampo L; Grau JJ; Taberna M; Rubió-Casadevall J; Martínez-Trufero J; Morillo EDB; García Girón C; Vázquez Estévez S; Cirauqui B; Cruz-Hernández JJ
Oral Oncol; 2022 Nov; 134():106087. PubMed ID: 36126605
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of cisplatin and weekly docetaxel in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
Kim MJ; Kim SM; Jung HA; Hong JY; Chang WJ; Choi MK; Kim HS; Sun JM; Park K; Ahn MJ
Korean J Intern Med; 2019 Sep; 34(5):1107-1115. PubMed ID: 29914230
[TBL] [Abstract][Full Text] [Related]
27. TEMHEAD: a single-arm multicentre phase II study of temsirolimus in platin- and cetuximab refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) of the German SCCHN Group (AIO).
Grünwald V; Keilholz U; Boehm A; Guntinas-Lichius O; Hennemann B; Schmoll HJ; Ivanyi P; Abbas M; Lehmann U; Koch A; Karch A; Zörner A; Gauler TC
Ann Oncol; 2015 Mar; 26(3):561-7. PubMed ID: 25527417
[TBL] [Abstract][Full Text] [Related]
28. Cetuximab plus platinum-based chemotherapy in head and neck squamous cell carcinoma: a randomized, double-blind safety study comparing cetuximab produced from two manufacturing processes using the EXTREME study regimen.
Soulières D; Aguilar JL; Chen E; Misiukiewicz K; Ernst S; Lee HJ; Bryant K; He S; Obasaju CK; Chang SC; Chin S; Adkins D
BMC Cancer; 2016 Jan; 16():19. PubMed ID: 26768732
[TBL] [Abstract][Full Text] [Related]
29. Modified biweekly cisplatin, docetaxel plus cetuximab (TPEx) as first-line treatment for patients with recurrent/metastatic head and neck cancer.
Fuchs H; Pammer J; Minichsdorfer C; Posch D; Kornek G; Aretin MB; Fuereder T
Med Oncol; 2018 Feb; 35(3):32. PubMed ID: 29411154
[TBL] [Abstract][Full Text] [Related]
30. Dose-dense TPF induction chemotherapy for locally advanced head and neck cancer: a phase II study.
Hsieh CY; Lein MY; Yang SN; Wang YC; Lin YJ; Lin CY; Hua CH; Tsai MH; Lin CC
BMC Cancer; 2020 Sep; 20(1):832. PubMed ID: 32873270
[TBL] [Abstract][Full Text] [Related]
31. Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study.
Kim S; François E; André T; Samalin E; Jary M; El Hajbi F; Baba-Hamed N; Pernot S; Kaminsky MC; Bouché O; Desrame J; Zoubir M; Ghiringhelli F; Parzy A; De La Fouchardiere C; Smith D; Deberne M; Spehner L; Badet N; Adotevi O; Anota A; Meurisse A; Vernerey D; Taieb J; Vendrely V; Buecher B; Borg C
Lancet Oncol; 2018 Aug; 19(8):1094-1106. PubMed ID: 30042063
[TBL] [Abstract][Full Text] [Related]
32. Postoperative chemoradiotherapy and cetuximab for high-risk squamous cell carcinoma of the head and neck: Radiation Therapy Oncology Group RTOG-0234.
Harari PM; Harris J; Kies MS; Myers JN; Jordan RC; Gillison ML; Foote RL; Machtay M; Rotman M; Khuntia D; Straube W; Zhang Q; Ang K
J Clin Oncol; 2014 Aug; 32(23):2486-95. PubMed ID: 25002723
[TBL] [Abstract][Full Text] [Related]
33. Weekly paclitaxel, carboplatin, cetuximab, and cetuximab, docetaxel, cisplatin, and fluorouracil, followed by local therapy in previously untreated, locally advanced head and neck squamous cell carcinoma.
Haddad RI; Massarelli E; Lee JJ; Lin HY; Hutcheson K; Lewis J; Garden AS; Blumenschein GR; William WN; Pharaon RR; Tishler RB; Glisson BS; Pickering C; Gold KA; Johnson FM; Rabinowits G; Ginsberg LE; Williams MD; Myers J; Kies MS; Papadimitrakopoulou V
Ann Oncol; 2019 Mar; 30(3):471-477. PubMed ID: 30596812
[TBL] [Abstract][Full Text] [Related]
34. Methotrexate plus or minus cetuximab as first-line treatment in a recurrent or metastatic (R/M) squamous cell carcinoma population of the head and neck (SCCHN), unfit for cisplatin combination treatment, a phase Ib-randomized phase II study Commence.
Ham JC; van Meerten E; Fiets WE; Beerepoot LV; Jeurissen FJF; Slingerland M; Jonker MA; Husson O; van der Graaf WTA; van Herpen CML
Head Neck; 2020 May; 42(5):828-838. PubMed ID: 31903657
[TBL] [Abstract][Full Text] [Related]
35. Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck: The Active8 Randomized Clinical Trial.
Ferris RL; Saba NF; Gitlitz BJ; Haddad R; Sukari A; Neupane P; Morris JC; Misiukiewicz K; Bauman JE; Fenton M; Jimeno A; Adkins DR; Schneider CJ; Sacco AG; Shirai K; Bowles DW; Gibson M; Nwizu T; Gottardo R; Manjarrez KL; Dietsch GN; Bryan JK; Hershberg RM; Cohen EEW
JAMA Oncol; 2018 Nov; 4(11):1583-1588. PubMed ID: 29931076
[TBL] [Abstract][Full Text] [Related]
36. Observational, prospective, phase 4 study in patients with first-line recurrent and/or metastatic squamous cell carcinoma of the head and neck treated with cetuximab and platinum-based therapy: DIRECT.
Guigay J; Chamorey E; Lefebvre G; Rotarski M; Wagner JP; Blot E; Alfonsi M; Seronde A; Schulten J; Peyrade F; Le Tourneau C
Cancer Rep (Hoboken); 2022 Feb; 5(2):e1467. PubMed ID: 34156166
[TBL] [Abstract][Full Text] [Related]
37. Docetaxel, cisplatin, and fluorouracil for patients with inoperable recurrent or metastatic head and neck squamous cell carcinoma.
Cho H; Nishiike S; Yamamoto Y; Takenaka Y; Nakahara S; Yasui T; Hanamoto A; Inohara H
Auris Nasus Larynx; 2015 Oct; 42(5):396-400. PubMed ID: 25721854
[TBL] [Abstract][Full Text] [Related]
38. Docetaxel, cisplatin and 5-fluorouracil in patients with locally advanced unresectable head and neck cancer: a phase I-II feasibility study.
Schrijvers D; Van Herpen C; Kerger J; Joosens E; Van Laer C; Awada A; Van den Weyngaert D; Nguyen H; Le Bouder C; Castelijns JA; Kaanders J; De Mulder P; Vermorken JB
Ann Oncol; 2004 Apr; 15(4):638-45. PubMed ID: 15033673
[TBL] [Abstract][Full Text] [Related]
39. Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
Bourhis J; Rivera F; Mesia R; Awada A; Geoffrois L; Borel C; Humblet Y; Lopez-Pousa A; Hitt R; Vega Villegas ME; Duck L; Rosine D; Amellal N; Schueler A; Harstrick A
J Clin Oncol; 2006 Jun; 24(18):2866-72. PubMed ID: 16717293
[TBL] [Abstract][Full Text] [Related]
40. Platinum-based chemotherapy plus cetuximab for the first-line treatment of Japanese patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: results of a phase II trial.
Yoshino T; Hasegawa Y; Takahashi S; Monden N; Homma A; Okami K; Onozawa Y; Fujii M; Taguchi T; de Blas B; Beier F; Tahara M
Jpn J Clin Oncol; 2013 May; 43(5):524-31. PubMed ID: 23479384
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
